Quantbot Technologies LP Sells 12,136 Shares of Zoetis Inc. $ZTS

Quantbot Technologies LP lowered its holdings in Zoetis Inc. (NYSE:ZTS) by 43.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 15,573 shares of the company’s stock after selling 12,136 shares during the period. Quantbot Technologies LP’s holdings in Zoetis were worth $2,279,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in ZTS. Vanguard Group Inc. grew its position in Zoetis by 1.0% during the third quarter. Vanguard Group Inc. now owns 42,306,764 shares of the company’s stock valued at $6,190,326,000 after buying an additional 419,777 shares during the period. Geode Capital Management LLC boosted its stake in Zoetis by 0.9% in the second quarter. Geode Capital Management LLC now owns 11,081,301 shares of the company’s stock valued at $1,721,356,000 after acquiring an additional 95,294 shares during the last quarter. Norges Bank purchased a new position in Zoetis in the second quarter valued at about $809,491,000. Brown Advisory Inc. grew its position in shares of Zoetis by 5.7% during the 2nd quarter. Brown Advisory Inc. now owns 4,659,371 shares of the company’s stock valued at $726,629,000 after acquiring an additional 250,829 shares during the period. Finally, Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in shares of Zoetis by 14.6% during the 3rd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,312,779 shares of the company’s stock worth $631,046,000 after purchasing an additional 550,859 shares during the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Price Performance

Shares of NYSE ZTS opened at $126.01 on Wednesday. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.94 and a current ratio of 3.03. Zoetis Inc. has a fifty-two week low of $115.25 and a fifty-two week high of $177.00. The stock has a market cap of $53.19 billion, a PE ratio of 20.93, a price-to-earnings-growth ratio of 1.97 and a beta of 0.95. The stock has a fifty day moving average of $126.21 and a 200-day moving average of $133.55.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.40 by $0.08. The business had revenue of $2.39 billion for the quarter, compared to analysts’ expectations of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The firm’s quarterly revenue was up 3.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.40 EPS. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Equities research analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be given a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.7%. The ex-dividend date is Monday, April 20th. Zoetis’s dividend payout ratio (DPR) is 35.22%.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on ZTS shares. HSBC set a $140.00 price objective on Zoetis in a research note on Wednesday, December 10th. William Blair reaffirmed an “outperform” rating on shares of Zoetis in a research report on Monday. The Goldman Sachs Group upgraded Zoetis to a “buy” rating in a research note on Monday, December 15th. KeyCorp initiated coverage on Zoetis in a report on Thursday, November 20th. They issued a “sector weight” rating for the company. Finally, Weiss Ratings cut Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, January 28th. Six analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $152.91.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.